Elena V. Bova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena V. Bova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra A. Demidova
Rostov State Medical University
2 shared publications - Ekaterina V. Verenikina
National Medical Research Centre for Oncology
2 shared publications - Mariya Yu. Grafskaya
National Medical Research Center of Oncology
2 shared publications - Aleksey Yur'EVich Maksimov
National Medical Research Centre for Oncology
1 shared publication - I. V. Dubatova
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
1 shared publication - M. I. Nazheva
ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России
1 shared publication
Latest Publications
- Open Access
- 22 September 2025
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 3,p. 24-28
Prospects for the detection of ovarian cancer by genetic testing of aspirate from the uterine cavity
In the article, a genetic study of biological samples from uterine cavity aspirate was performed in patients with serous ovarian carcinoma in order to identify gene mutations characteristic of ovarian tumor lesions. It has been proven that the aspiration from the uterine cavity contains diagnostically significant numbers of cells or fragments of ovarian cancer cells necessary for molecular genetic analysis and detection of mutations in the TP53, FAT3, CSMD3, BRAF, and KRAS genes. Mutations of the BRCA1/2 genes are rare. The detection of TP53, FAT3, CSMD3, BRAF, and KRAS gene mutations in uterine aspirate cells requires an active diagnostic search for the detection of ovarian serous carcinoma.
- 22 September 2025
- Published by Yakutsk Scientific Center for Complex Medical Problems in Yakut Medical Journal
- No. 3,p. 24-28
Open AccessProspects for the detection of ovarian cancer by genetic testing of aspirate from the uterine cavity
In the article, a genetic study of biological samples from uterine cavity aspirate was performed in patients with serous ovarian carcinoma in order to identify gene mutations characteristic of ovarian tumor lesions. It has been proven that the aspiration from the uterine cavity contains diagnostically significant numbers of cells or fragments of ovarian cancer cells necessary for molecular genetic analysis and detection of mutations in the TP53, FAT3, CSMD3, BRAF, and KRAS genes. Mutations of the BRCA1/2 genes are rare. The detection of TP53, FAT3, CSMD3, BRAF, and KRAS gene mutations in uterine aspirate cells requires an active diagnostic search for the detection of ovarian serous carcinoma.
- 5 August 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (4) , 563-569
Effectiveness of adding molecular-genetic testing to liquid-based papanicolaou cytology for detecting endometrial cancer in women with comorbidities
BACKGROUND: Developing an effective screening strategy for women with morbid obesity using accessible and simple biological sampling methods remains critical. AIM: This study aimed to evaluate the effectiveness of additional molecular genetic testing of cervical canal biopsy samples in detecting endometrial cancer in women with morbid obesity. METHODS: Overall, 378 patients with endometrial cancer were examined. Two groups were formed based on comorbid status: the study group (n = 103) with morbid obesity and comparison group (n = 275) without obesity. The control group included 226 women without oncologic conditions: 47 with morbid obesity and 179 without obesity. Cervical canal samples were collected by brush biopsy. Extracted DNA was amplified using polymerase chain reaction to detect oncogenic mutations in 18 genes. RESULTS: Oncogenic mutations were identified in endocervical scrapings more frequently in the study group (82.5%; p = 0.042) than in the comparison group (72.4%). In the control group, oncogenic mutations were rare and not significantly associated with obesity (8.5% vs 3.9%; p = 0.193). In patients with endometrial cancer and morbid obesity, mutation detection increased, and the spectrum of mutated genes was broader. The most informative genes for screening were PTEN, TP53, PIK3CA, PIK3R1, CTNNB1, KRAS, FBXW7, FGFR2, APC, and POLE. CONCLUSION: Molecular testing for oncogenic mutations in cervical liquid-based cytology samples is an effective endometrial cancer screening method. The presence of morbid obesity enhances the test’s diagnostic yield and expands the range of detectable mutations.
- 5 August 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (4) , 563-569
Effectiveness of adding molecular-genetic testing to liquid-based papanicolaou cytology for detecting endometrial cancer in women with comorbidities
BACKGROUND: Developing an effective screening strategy for women with morbid obesity using accessible and simple biological sampling methods remains critical. AIM: This study aimed to evaluate the effectiveness of additional molecular genetic testing of cervical canal biopsy samples in detecting endometrial cancer in women with morbid obesity. METHODS: Overall, 378 patients with endometrial cancer were examined. Two groups were formed based on comorbid status: the study group (n = 103) with morbid obesity and comparison group (n = 275) without obesity. The control group included 226 women without oncologic conditions: 47 with morbid obesity and 179 without obesity. Cervical canal samples were collected by brush biopsy. Extracted DNA was amplified using polymerase chain reaction to detect oncogenic mutations in 18 genes. RESULTS: Oncogenic mutations were identified in endocervical scrapings more frequently in the study group (82.5%; p = 0.042) than in the comparison group (72.4%). In the control group, oncogenic mutations were rare and not significantly associated with obesity (8.5% vs 3.9%; p = 0.193). In patients with endometrial cancer and morbid obesity, mutation detection increased, and the spectrum of mutated genes was broader. The most informative genes for screening were PTEN, TP53, PIK3CA, PIK3R1, CTNNB1, KRAS, FBXW7, FGFR2, APC, and POLE. CONCLUSION: Molecular testing for oncogenic mutations in cervical liquid-based cytology samples is an effective endometrial cancer screening method. The presence of morbid obesity enhances the test’s diagnostic yield and expands the range of detectable mutations.